Induced apoptosis in the prevention of colorectal cancer by non- steroidal anti-inflammatory drugs

Apoptosis

Volumn 4, Issue 5, 1999, Pages 365-372

  Elder, Douglas J E ^a   Paraskeva, C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Apoptosis; Chemoprevention; Colorectal cancer; Cyclooxygenase; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SALICYLIC ACID; SULINDAC; SULINDAC SULFIDE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL TRANSFORMATION; COLORECTAL CANCER; DRUG ACTIVITY; DRUG METABOLISM; HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION;

EID: 0032729708     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009696505108     Document Type: Article

References (46)

1. Thun MJ. NSAID use and decreased risk of gastrointestinal cancers. In: DuBois RN and Giardiello FM, eds. NSAIDs, Eicosanoids, and the Gastroenteric Tract. Gastroenterology Clinics of North America, Vol. 25. Philadelphia: Saunders, 1996: 333-348.
2. Giariello FM. NSAID-induced polyp regression in familial adenomatous polyposis patients. In: DuBois RN and Giardiello FM, eds. NSAIDs, Eicosanoids, and the Gastroenteric Tract. Gastroenterology Clinics of North America, Vol. 25. Philadelphia: Saunders, 1996: 349-361.
3. 2. Gut 1994; 35: 675-678.
4. Qiao L, Kozoni V, Tsioulias GJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim et Biophys Acta 1995; 1258: 215-223.
5. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188.
6. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785-3789.
7. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55, 2556-2559.
8. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93: 4816-4820.
9. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
10. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-3340.
11. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
12. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-809.
13. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997; 57: 2909-2915.
14. Thompson HJ, Jiang C, Lu J, et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 1997; 57: 267-271.
15. + mouse model: Implications for prophylaxis and treatment of colon cancer. Cancer Res 1997; 57: 4316-4324.
16. Elder DJE, Paraskeva C. COX-2 inhibitors for colorectal cancer. Nature Med 1998; 4: 392-393.
17. van Stolk R, Budd GT, Kresty R, et al. Effect of sulindac sulfone on proliferation, apoptosis and polyps in a clinical trial in familial adenomatous polyposis (FAP) with rectal polyps. Gastroenterology 1998; 114 (4): G2881.
18. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55: 1811-1816.
19. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA 1996; 93: 7950-7954.
20. Shiff SJ, Qiao L, Tsai L, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinma cells. J Clin Invest 1995; 96: 491-503.
21. Piazza GA, Rahm ALK, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55: 3110-3116.
22. Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997; 57: 2452-2459.
23. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin - independent pathway. Biochem Pharmacol 1996; 52: 237-245.
24. Shiff SJ, Koutsos MI, Qiao L, Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis. Exp Cell Res 1996; 222: 179-188.
25. Qiao L, Hanif R, Sphicas E, Shiff SJ, Rigas B. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem Pharmacol 1998; 55: 53-64.
26. Elder DJE, Hague A, Hicks DJ, Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: Enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res 1996; 56: 2273-2276.
27. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994-998.
28. Keller JJ, Offerhaus GJA, Goodman SN, et al. Change in apoptosis in patients treated with sulindac. Gastroenterology 1998; 114(4): G2550.
29. Goldberg Y, Nassif II, Pittas A, et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996; 12: 893-901.
30. Ricchi P, Pignata S, Di Popolo A, et al. Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. Int J Cancer 1997; 73: 880-884.
31. Wallace, JL Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years. Gastroenterology 1997; 112: 1000-1016.
32. Takahashi M, Fukutake M, Yokota S, Ishida K, Wakabayashi K, Sugimura T. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. J Cancer Res Clin Oncol 1996; 122, 219-222.
33. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566-4569.
34. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemoprevention activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-412.
35. Hara A, Yoshimi N, Niwa M, Ino N, Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Japanese Jnl Cancer Res 1997; 88: 600-604.
36. Elder DJE, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997; 3: 1679-1683.
37. Sheng GG, Shao J, Sheng H, et al. A selective cyclooxygenase-2 inhibitor (SC-58125) suppresses the growth of H-ras Transformed rat intestinal epithelial cells. Gastroenterology 1997; 113: 1883-1891.
38. Arber N, Han EK, Sganbato A, et al. A K-ras oncogene increases resistance to sulindac-induced apoptosis in rat enterocytes. Gastroenterology 1997; 113: 1892-1990.
39. Bouck N. p53 and angiogenesis. Biochem Biophys Acta 1995; 1287: 63-66.
40. Harris N, Kaznov D, Pick M, et al. c-K-ras transformed rat enterocytes (R1) are more sensitive than normal enterocytes (IEC18) to growth inhibition and apoptosis-induced by sulindac sulfone and nimesulid. Gastroenterology 1998; 114(4): G2496.
41. Singh J, Kulkarni N, Kelloff G, Reddy BS. Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis. Carcinogenesis 1994; 15: 1317-1323.
42. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998; 95: 681-686.
43. 2 in human colon cancer cells. Cancer Res 1998; 58: 362-366.
44. Elder DJE, Halton DE, Paraskeva C. Cellular and molecular effects of a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug on colorectal adenoma and carcinoma cell lines. Gastroenterology 1998; 114(4): G2416.
45. Chulada PC, Doyle C, Gaul B, et al. Cyclooxygenase-1 and -2 deficiency decrease spontaneous intestinal adenomas in the Min mouse. Proc Am Assoc Cancer Res 1998; 39: 195.
46. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 97: 2254-2259.